enGene Therapeutics (ENGN) Operating Income (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Operating Income of -$32.0 million for Q2 2026, down 17.86% year-over-year from -$38.9 million in Q2 2025, and down 2.51% quarter-over-quarter from -$31.2 million in Q1 2026.
enGene Therapeutics (ENGN) Operating Income (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Operating Income for 4 consecutive years, with -$32.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Income fell 17.86% year-over-year to -$32.0 million; the TTM figure through Apr 2026 stood at -$132.6 million (down 50.74% YoY), while the FY2025 annual figure was -$123.2 million, down 97.71% from the prior year.
- Operating Income retreated to -$32.0 million in Q2 2026 per ENGN's latest filing, from -$31.2 million in the prior quarter.
- Across five years, Operating Income topped out at -$4.6 million in Q1 2023 and bottomed at -$39.5 million in Q4 2025.
- Historically, Operating Income has averaged -$19.6 million across 4 years, with a median of -$17.4 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Income plunged 265.42% — and 2026, when it retreated 17.18%.
- enGene Therapeutics' Operating Income stood at -$10.4 million in 2023, then tumbled by 67.16% to -$17.5 million in 2024, then slumped by 126.19% to -$39.5 million in 2025, then grew by 19.03% to -$32.0 million in 2026.
- Business Quant data shows ENGN's Operating Income at -$32.0 million in Q2 2026, -$31.2 million in Q1 2026, and -$39.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | -31.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -31.97 Mn |
| Jan 31, 2026 | -31.19 Mn |
| Oct 31, 2025 | -39.48 Mn |
| Jul 31, 2025 | -29.95 Mn |
| Apr 30, 2025 | -27.12 Mn |
| Jan 31, 2025 | -26.61 Mn |
| Oct 31, 2024 | -17.46 Mn |
| Jul 31, 2024 | -16.76 Mn |
| Apr 30, 2024 | -17.31 Mn |
| Jan 31, 2024 | -10.77 Mn |
| Oct 31, 2023 | -10.44 Mn |
| Jul 31, 2023 | -6.25 Mn |
| Apr 30, 2023 | -4.74 Mn |
| Jan 31, 2023 | -4.63 Mn |